U.S. Markets open in 4 hrs 34 mins
  • S&P Futures

    4,069.00
    +64.25 (+1.60%)
     
  • Dow Futures

    32,541.00
    +382.00 (+1.19%)
     
  • Nasdaq Futures

    12,517.00
    +272.25 (+2.22%)
     
  • Russell 2000 Futures

    1,813.60
    +31.20 (+1.75%)
     
  • Crude Oil

    114.48
    +0.28 (+0.25%)
     
  • Gold

    1,827.20
    +13.20 (+0.73%)
     
  • Silver

    21.80
    +0.24 (+1.13%)
     
  • EUR/USD

    1.0487
    +0.0048 (+0.4614%)
     
  • 10-Yr Bond

    2.8770
    0.0000 (0.00%)
     
  • Vix

    26.68
    -2.19 (-7.59%)
     
  • GBP/USD

    1.2465
    +0.0142 (+1.1493%)
     
  • USD/JPY

    129.3780
    +0.3250 (+0.2518%)
     
  • BTC-USD

    30,604.69
    +826.89 (+2.78%)
     
  • CMC Crypto 200

    686.82
    +444.14 (+183.01%)
     
  • FTSE 100

    7,517.91
    +53.11 (+0.71%)
     
  • Nikkei 225

    26,659.75
    +112.70 (+0.42%)
     

HHS says Gilead, distributor can directly sell COVID-19 drug in U.S.

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Oct 1 (Reuters) - The U.S. Department of Health and Human Services (HHS) said on Thursday that U.S. hospitals can now buy Gilead Sciences Inc's antiviral COVID-19 drug remdesivir from the company and its distributor.

The drug, branded as Veklury, was being distributed across the United States by HHS.

Gilead said it is now meeting real-time demand for remdesivir in the U.S. and anticipates meeting global demand for the drug in October, even in the event of potential future surges of COVID-19.

Gilead donated courses of the drug after it was authorized in May for use in patients with a severe form of COVID-19. Trial data showed the antiviral drug helped shorten hospital recovery time.

AmerisourceBergen will continue to serve as the sole U.S. distributor of remdesivir through the end of this year and will sell the product directly to hospitals, Gilead said.

(Reporting by Manas Mishra in Bengaluru; Editing by Amy Caren Daniel)